University of Oxford/AstraZeneca vaccine approved

Matthew Fell, CBI Chief UK Policy Director, said:
“Approval of the Oxford/AstraZeneca vaccine is hugely positive news, and a real feather in the cap for the UK life sciences sector. It adds another weapon to the UK’s pandemic arsenal, bringing us one step closer to returning to a more normal way of life.
“This is not the end of the battle, though. Rising infection rates and new strains mean tough precautions remain necessary in the short-term. Businesses understand this and continue to do their utmost to protect their staff and customers.
“In turn, Government must continue to do all it can to protect businesses. It must ensure ongoing restrictions are grounded in evidence, continue to roll out an improved testing regime which will enable more parts of the economy to reopen safely, and ensure financial support for the hardest-hit sectors remains in place until the pandemic is past.”